Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 26;16(1):48.
doi: 10.1186/s13023-021-01698-4.

Clinicopathological features of fibrosarcomatous dermatofibrosarcoma protuberans and the construction of a back-propagation neural network recognition model

Yanan Li #  1 , Jiaqi Liang #  2 , Xuewen Xu  3 , Xian Jiang  4 , Chuan Wang  1 , Siyuan Chen  5 , Bo Xiang  6 , Yi Ji  7
Affiliations

Clinicopathological features of fibrosarcomatous dermatofibrosarcoma protuberans and the construction of a back-propagation neural network recognition model

Yanan Li et al. Orphanet J Rare Dis. .

Abstract

Background: Fibrosarcomatous dermatofibrosarcoma protuberans (FS-DFSP) is a form of tumor progression of dermatofibrosarcoma protuberans (DFSP) with an increased risk of metastasis and recurrence. Few studies have compared the clinicopathological features of FS-DFSP and conventional DFSP (C-DFSP).

Objectives: To better understand the epidemiological and clinicopathological characteristics of FS-DFSP.

Methods: We conducted a cohort study of 221 patients diagnosed with DFSP and built a recognition model with a back-propagation (BP) neural network for FS-DFSP.

Results: Twenty-six patients with FS-DFSP and 195 patients with C-DFSP were included. There were no differences between FS-DFSP and C-DFSP regarding age at presentation, age at diagnosis, sex, size at diagnosis, size at presentation, and tumor growth. The negative ratio of CD34 in FS-DFSP (11.5%) was significantly lower than that in C-DFSP (5.1%) (P = 0.005). The average Ki-67 index of FS-DFSP (18.1%) cases was significantly higher than that of C-DFSP (8.1%) cases (P < 0.001). The classification accuracy of the BP neural network model training samples was 100%. The correct rates of classification and misdiagnosis were 84.1% and 15.9%.

Conclusions: The clinical manifestations of FS-DFSP and C-DFSP are similar but have large differences in immunohistochemistry. The classification accuracy and feasibility of the BP neural network model are high in FS-DFSP.

Keywords: BP neural network; Clinicopathological features; Dermatofibrosarcoma protuberans; Fibrosarcomatous.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests, either financial or non-financial, that could be perceived as prejudicing the impartiality of the research reported.

Figures

Fig. 1
Fig. 1
Histopathological examination. a DFSP without fibrosarcomatous change showing spindle cells (H&E, original magnification × 200). b DFSP with fibrosarcomatous change showing a fascicular growth pattern (H&E, original magnification × 200)
Fig. 2
Fig. 2
The topological structure of the BP neural network
Fig. 3
Fig. 3
Age distribution at presentation and first diagnosis in patients with FS-DFSP and C-DFSP (Y-axis: number of patients, X-axis: years). a Age at presentation; b age at first diagnosis
Fig. 4
Fig. 4
The results of the BP neural network model: a the result of the training set; b the result of the test set
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer. 2004;101(11):2503–2508. doi: 10.1002/cncr.20678. - DOI - PubMed
    1. Bendix-Hansen K, Myhre-Jensen O, Kaae S. Dermatofibrosarcoma protuberans. A clinico-pathological study of nineteen cases and review of world literature. Scand J Plast Reconstr Surg. 1983;17(3):247–252. doi: 10.3109/02844318309013125. - DOI - PubMed
    1. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007;56(6):968–973. doi: 10.1016/j.jaad.2006.09.006. - DOI - PubMed
    1. Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42(Suppl 1):S24–31. doi: 10.1097/DSS.0000000000000300. - DOI - PubMed
    1. Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88(12):2711–2720. doi: 10.1002/1097-0142(20000615)88:12<2711::AID-CNCR9>3.0.CO;2-M. - DOI - PubMed

Publication types